Literature DB >> 6537801

Acute effects of cis-diamminedichloroplatinum (CDDP) on renal function.

J J Offerman, S Meijer, D T Sleijfer, N H Mulder, A J Donker, H S Koops, G K van der Hem.   

Abstract

Ten previously untreated patients with metastatic non-seminomatous testicular carcinoma received cis-diamminedichloroplatinum (CDDP). Renal function studies were performed before and following the first CDDP infusion. A decrease in effective renal plasma flow (ERPF) and an increase in filtration fraction (FF) was found in all patients. These findings suggest primary changes in renal hemodynamics during CDDP infusion.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6537801     DOI： 10.1007/bf00255906

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  14 in total

1.  Pathophysiology of a nephrotoxic model of acute renal failure.

Authors:  J H Stein; J Gottschall; R W Osgood; T F Ferris
Journal:  Kidney Int       Date:  1975-07       Impact factor: 10.612

2.  Considerations on the pathophysiology of mercuric chloride-induced acute renal failure.

Authors:  R W Baehler; T A Kotchen; J A Burke; J H Galla; D Bhathena
Journal:  J Lab Clin Med       Date:  1977-08

3.  A radioisotope method for simultaneous determination of the glomerular filtration rate and the effective renal plasma flow.

Authors:  A J Donker; G K van der Hem; W J Sluiter; H Beekhuis
Journal:  Neth J Med       Date:  1977       Impact factor: 1.422

4.  Experimental acute renal failure induced by uranyl nitrate in the dog.

Authors:  W Flamenbaum; J S McNeil; T A Kotchen; A J Saladino
Journal:  Circ Res       Date:  1972-11       Impact factor: 17.367

5.  Long-term treatment with cis-dichlorodiammineplatinum(II)-vinblastine-bleomycin: possible association with severe coronary artery disease.

Authors:  G S Edwards; M Lane; F E Smith
Journal:  Cancer Treat Rep       Date:  1979-04

6.  Some effects of combination chemotherapy with cis-platinum on renal function in patients with nonseminomatous testicular carcinoma.

Authors:  S Meijer; D T Sleijfer; N H Mulder; W J Sluiter; J Marrink; H S Koops; T M Brouwers; J Oldhoff; G K van der Hem; E Mandema
Journal:  Cancer       Date:  1983-06-01       Impact factor: 6.860

7.  Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer.

Authors:  N J Vogelzang; G J Bosl; K Johnson; B J Kennedy
Journal:  Ann Intern Med       Date:  1981-09       Impact factor: 25.391

8.  Renal vascular lesions after chemotherapy with vinblastine, bleomycin, and cisplatin.

Authors:  R M Harrell; R Sibley; N J Vogelzang
Journal:  Am J Med       Date:  1982-09       Impact factor: 4.965

9.  Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer.

Authors:  L H Einhorn; J Donohue
Journal:  Ann Intern Med       Date:  1977-09       Impact factor: 25.391

10.  Nephrotoxicity of cis-diamminedichloride platinum (CDDP) during remission-induction and maintenance chemotherapy of testicular carcinoma.

Authors:  S Meijer; N H Mulder; D T Sleijfer; P E de Jong; W J Sluiter; H Schraffordt Koops; G K van der Hem
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333
View more
  19 in total

Review 1.  Cisplatin nephrotoxicity. A review.

Authors:  G Daugaard; U Abildgaard
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Evaluation of the effect of furosemide on ultrafilterable platinum kinetics in patients treated with cis-diamminedichloroplatinum.

Authors:  M Dumas; C de Gislain; P d'Athis; V Chadoint-Noudeau; A Escousse; J Guerrin; N Autissier
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

3.  The protective effect of royal jelly against cisplatin-induced renal oxidative stress in rats.

Authors:  Sibel Silici; Oguz Ekmekcioglu; Murat Kanbur; Kemal Deniz
Journal:  World J Urol       Date:  2010-04-06       Impact factor: 4.226

Review 4.  Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review.

Authors:  V Pinzani; F Bressolle; I J Haug; M Galtier; J P Blayac; P Balmès
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 5.  Assessment of chemotherapy-associated nephrotoxicity in children with cancer.

Authors:  R Skinner; A D Pearson; M G Coulthard; A W Skillen; A W Hodson; M E Goldfinch; I Gibb; A W Craft
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

6.  Successful treatment of Cisplatin overdose with plasma exchange.

Authors:  Yasuhiro Yamada; Yoshiaki Ikuta; Kisato Nosaka; Nobutomo Miyanari; Naoko Hayashi; Hiroaki Mitsuya; Hideo Baba
Journal:  Case Rep Med       Date:  2010-03-11

7.  Influence of hydration on ultrafilterable platinum kinetics and kidney function in patients treated with cis-diamminedichloroplatinum(II).

Authors:  M Dumas; C de Gislain; P d'Athis; V Chadoint-Noudeau; A Escousse; J Guerrin; N Autissier
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 8.  Cisplatin: a review of clinical applications and renal toxicity.

Authors:  D T Sleijfer; S Meijer; N H Mulder
Journal:  Pharm Weekbl Sci       Date:  1985-12-13

9.  Urinary beta 2-microglobulin: early indicator of high dose cisdiamminedichloroplatinum nephrotoxicity? Influence of furosemide.

Authors:  C de Gislain; M Dumas; P d'Athis; J L Lautissier; A Escousse; J Guerrin
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

10.  Renal immunolocalization of kallikrein in cisplatin nephrotoxicity in rats.

Authors:  C Orfila; G Bompart; J C Lepert; J M Suc; J P Girolami
Journal:  Histochem J       Date:  1993-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.